year. Preventive medicines are used in treatment of migraines with abortive medicines treating the
even more serious cases and reduce the intense and sporadic pain to a large extent.
The growth drivers for anti-migraine drugs market comes from the growing faction of severe and
ever-increasing migraine sufferers and incidences of increased awareness and technological
breakthroughs in anti-migraine drugs. Restraints such as patent withdrawals and high generalizations
with entry of local entities may restrain anti-migraine drugs market for anti-migraine drug market.
Drugs for treatment of migraine end up as triptans such as sumatriptan, zolmitriptan.
It is of the opinion that many launches of generic drugs will severely impact drug treatment rates in
positive manner and will augment diagnosis leading to sustained global growth of anti-migraine drugs
market during forecast period. The anti-migraine drugs Industry is dominated by triptans and most of
the medicines are available as pills. Triptans such as sumatriptan are also available as nasal sprays
whereas riazatriptan and zolmitriptans re available as tablets that dissolve in mouth or orally
disintegrating tablets (ODT). Some may get warning symptoms before the start of the migraine
headache.
Request Sample Copy of this Market Research @
https://www.millioninsights.com/industry-reports/anti-migraine-drugs-market/request-sample
By region, anti-migraine drugs market includes North America, Europe, Asia pacific, MEA and Latin
America. The key industrial players in the anti-migraine drugs sales market include Abbott
Laboratories, Inc., Eisai Inc., Eli lilly and Company, Pfizer Inc., Astra Zeneca plc. and Glaxo SmithKline
Plc.
Market Segment:
Geographically, this report is segmented into several key Regions, with production, consumption,
revenue (million USD), market share and growth rate of Anti-Migraine Drugs in these regions,
from 2012 to 2022 (forecast), covering
• North America
• Europe
• China
• Japan